BioSpace News Archive

Alumis Inc. announced the pricing of its initial public offering of 13,125,000 shares of common stock at an initial public offering price of $16.00 per share.

Genmab A/S announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of conditional marketing authorization of epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of epcoritamab, the first and only T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies.

SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages to prevent and treat bacterial infections, announced that it has received funding from the Bill & Melinda Gates Foundation to develop a microbiome-directed intervention designed to improve environmental enteric dysfunction by reducing gut entero-pathogen burden in pregnant women from low- and middle-income countries.

Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.

Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes.

Spineart, a fast-growing company specialized in spine surgery innovation, is pleased to announce the appointment of Laurent Nodé-Langlois as Chief Technology Officer.

PTC Therapeutics, Inc. announced that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ for the treatment of nmDMD.

IDEAYA Biosciences, Inc. announced that, on June 27, 2024, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to two newly hired employees.

EvoEndo®, Inc. announces that Duke Health is the first provider in the region to bring Sedation-Free TNE of the Upper Gastrointestinal Tract using the EvoEndo® Single-Use Endoscopy System to patients in North Carolina.